News
08.04.2020
SOLNATIDE has been approved by the Austrian Federal Office for Safety in Health Care for the treatment of COVID-19 patients with severe pulmonary dysfunction
08.04.2020
Security of supply during the coronavirus crisis: ABF Pharmaceutical Services classified as "critical infrastructure" by the Federal Chancellery
06.04.2020
Versorgungssicherheit in Corona-Zeiten: ABF Pharmaceutical Services vom Bundeskanzleramt als „kritische Infrastruktur“ eingestuft
02.04.2020
APEIRON Biologics Initiates Phase II Clinical Trial of APN01 for Treatment of COVID-19
02.04.2020
PRAEVENIRE: Forschung als Motor für den Pharma- und Medizinprodukte-Standort Österreich
01.04.2020
COVID-19 und Herz-Kreislauf-Erkrankungen: "Je schwerer die Grunderkrankung, desto gefährdeter"
01.04.2020
APEPTICO has signed the Grant Agreement with the European Commission for the accelerated development and clinical use of the development compound SOLNATIDE for the treatment of COVID-19 patients
30.03.2020
Hilfe gegen Corona: Uni-Team Österreich etabliert neuen Antikörpertest aus dem New Yorker Mount Sinai Hospital